AbbVie
AI Intelligence Briefcase
Synthesize all available public data, government contracts, patent filings, and funding rounds for AbbVie into a comprehensive strategic report.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No recent patents found.
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
AbbVie Inc (NYSE:ABBV) Breakout Setup Combines Strong Technical Rating with High-Quality Consolidation Entry
A technical breakout strategy combining strong uptrend stocks with tight consolidation patterns for low-risk entry points, using AbbVie (ABBV) as a key example.
This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie
For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV) just got a lot easier to answer. The company posted $15.002 billion in Q1 2026 revenue, beating consensus by $284 million, and management raised full-year adjusted EPS guidance to $14.08 to $14.28. With the stock yielding nearly 3%, the question is whether the ... This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie
AbbVie: Maintaining My Strong Buy Rating After Label Expansion
AbbVie (ABBV) outlook: Skyrizi & Rinvoq drive growth as Humira fades. Read the full analysis here.
AbbVie Stock Will Hit $300 on This Date
AbbVie (NYSE:ABBV) has quietly become one of healthcare’s most underrated growth stories. CEO Robert A. Michael told investors after Q1, “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations.” The numbers back him up. Immunology revenue hit $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%. Yet shares ... AbbVie Stock Will Hit $300 on This Date
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture, leading to an improved neck appearance.1
AbbVie's Allergan Aesthetics Receives FDA Approval For SKINVIVE By JUVÉDERM To Reduce Neck Lines To Enhance Neck Appearance In Adults Over Age 21
Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults
Final Trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
The Investment Committee give you their top stocks to watch for the second half.
AbbVie (ABBV) Valuation Check After New Cancer And Migraine Drug Approvals
AbbVie (ABBV) is back in focus after a cluster of regulatory decisions, including FDA approval of DECNUPAZ for a rare blood cancer and European green lights for AQUIPTA and new VENCLYXTO combinations. See our latest analysis for AbbVie. The recent approvals have coincided with building momentum in the stock, with a 1 month share price return of 10.83% and a 1 year total shareholder return of 23.60%, while the 3 year total shareholder return sits at 83.11%. If these developments caught your...
AbbVie (ABBV) Announces European Commission’s Approval of AQUIPTA®
AbbVie Inc. (NYSE:ABBV) is one of the best cheap stocks to buy for beginners. AbbVie Inc. (NYSE:ABBV) announced on June 2 that the European Commission approved AQUIPTA® for the acute treatment of migraine in adults with or without aura, to be taken as needed. Management stated that the approval marks the second indication for AQUIPTA in […]
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro